NCT01738646View on ClinicalTrials.gov

Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

February 29, 2016

Conditions

Recurrent Glioblastoma MultiformeMalignant GliomaAdult Brain Tumor

Interventions

DRUG

Vorinostat

DRUG

Bevacizumab

Trial Locations (1)

27710

Duke Cancer Center, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Duke University

OTHER

NCT01738646 - Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients | Biotech Hunter | Biotech Hunter